ABCG2 expression in colorectal adenocarcinomas may predict resistance to irinotecan. by TUY Hoang Dinh
ABCG2 expression in colorectal adenocarcinomas
may predict resistance to irinotecan












ONCOLOGY LETTERS  12:  2752-2760,  20162752
Abstract. Irinotecan is a key drug for patients with advanced 
and recurrent colorectal carcinoma. However, the efficacy 
of irinotecan is not sufficient; partly, as there is no useful 
marker to predict chemosensitivity to the drug. The aim of the 
present study was to evaluate whether the expression levels 
of adenosine triphosphate-binding cassette sub-family G 
(WHITE) member 2 (Junior blood group) (ABCG2) in primary 
colorectal tumors predict chemoresistance to irinotecan. 
Using the resected primary tumor specimens of 189 patients 
with colorectal cancer, the association between the immuno-
histochemical expression of ABCG2 protein and the results 
of the collagen gel droplet embedded culture drug sensitivity 
test, performed to evaluate the chemosensitivity to SN-38 (an 
active metabolite of irinotecan), was investigated. Among 
the 189 patients, 17 received irinotecan-based chemotherapy, 
and their responses and progression-free survival (PFS) were 
analyzed. The tumors of patients with increased ABCG2 
expression accounted for 60% of the tumors examined, and 
were significantly more resistant to SN-38, compared with 
patients with low ABCG2 expression (P<0.001). In a multi-
variate logistic regression analysis, increased expression of 
ABCG2 protein was an independent and significant predictor 
of resistance to SN-38, increasing the risk of resistance by 
12-fold. Increased expression of ABCG2 and a low sensitivity 
to SN-38 was significantly associated with resistance to irino-
tecan-based chemotherapy (P=0.01 and 0.028, respectively). 
The median PFS of patients with increased expression of 
ABCG2 was significantly shorter, compared with patients with 
low expression levels of ABCG2 (104 vs. 242 days; P=0.047). 
The increased immunohistochemical expression of ABCG2 
in primary tumors may be a useful predictive biomarker of 
resistance to irinotecan-based chemotherapy for patients with 
recurrent or metastatic colorectal cancer.
Introduction
Colorectal cancer is the third most common malignancy and 
the fourth most lethal type of cancer in the world (1). Recur-
rence and metastases frequently occur in affected patients 
during the course of the disease, and chemotherapy is the 
major management strategy. Irinotecan is considered to be 
an essential component of first- and second-line treatments 
for metastatic or recurrent colorectal cancer, as 5-FU and 
leucovorin (FOLFIRI) ± molecular target drug, although other 
regimens, such as FOLFOX and CapeOX ± molecular target 
drug, are also considered good options (2). Current guidelines 
report that the selection of a specific chemotherapy regimen at 
present is solely based on the response to previous therapies or 
treatments in trials (2). Therefore, treatment results for patients 
with colorectal cancer have been far from satisfactory, with a 
response rate of ~50% for irinotecan-based combinations (2).
Certain predictive markers for the response of colorectal 
cancer to chemotherapy have been identified, including micro-
satellite instability, thymidylate synthase, dihydropyrimidine 
dehydrogenase for 5-fluorouracil (5-FU), excision repair 
cross-complementing protein 1 for oxaliplatin and mutations 
in Kirsten rat sarcoma viral oncogene homolog, and B-Raf 
proto-oncogene, serine/threonine kinase for panitumumab 
and cetuximab (3,4). In addition, numerous studies have been 
designed to indicate novel predictors of cellular response 
to irinotecan in vitro, including topoisomerase-I and -II, 
membrane transporter proteins, carboxylesterase, glucuronos-
yltransferases and proteasome (5,6). However, these predictors 
have not been proved to be effective in clinical studies (7).
Multidrug resistance is a serious problem, and is consid-
ered one of the major causes of chemotherapy failure. 
Multidrug resistance is often associated with the overex-
pression of adenosine triphosphate-binding cassette (ABC) 
transporter proteins, including ABCB1, ABCC1, ABCC2 and 
ABCG2 (8). Expression of ABCG2 has been observed in the 
epithelial cells of the intestine, colon, liver canaliculi, renal 
tubules and placenta, where it eliminates anticancer drugs and 
ingested toxins (9). The association between overexpression 
of ABCG2, response to chemotherapy and prognosis has been 
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reported for leukemia (10) and various solid tumors, including 
breast cancer (11), oral squamous cell carcinoma (12), 
esophageal cancer (13) and lung cancer (14). Irinotecan and 
its active metabolite, SN-38, are included among the transport 
substrates of ABCG2 (15). ABCG2 is abundant in the normal 
colon, and its expression is decreased in colorectal cancer. 
The downregulation of ABCG2 expression may have a role in 
tumorigenesis by enabling the accumulation of genotoxins and 
the overproduction of nitric oxide (16). The overexpression of 
ABCG2 protein in colon cancer cell lines has been associated 
with increased levels of resistance to SN-38 in vitro (17).
The aim of the present study was to assess whether the 
immunohistochemical expression of ABCG2 may be a poten-
tial predictor of the response to irinotecan-based treatment 
of patients with colorectal cancer. The results of the present 
study indicated that the increased expression of ABCG2 was 
associated with resistance to SN-38 in colorectal cancer and a 
negative response to irinotecan-based chemotherapy.
Materials and methods
Patients. The Ethics Committee of Shiga University of 
Medical Science (Otsu, Japan) approved this study. Signed 
informed consent was obtained prior to surgery from each of 
the 189 patients that underwent a colorectal resection at the 
Department of Surgery, Shiga University of Medical Science 
Hospital, between May 2004 and May 2012. All patients were 
chemotherapy-naive. The resected tumors were histologically 
confirmed as adenocarcinoma, and the chemosensitivities 
of the tumors to SN-38 and 5-FU were measured using the 
collagen gel droplet embedded culture drug sensitivity test 
(CD-DST). Among the 189 patients enrolled in the study, 
17 underwent irinotecan-based chemotherapy for ≥2 months. 
The cancer statuses of all 17 patients were recurrent and 
unresectable. The patients received no surgical or radiation 
interventions during the period of chemotherapy. A total of 
13 patients received the FOLFIRI regimen; Irinotecan at a 
dose of 120 mg/m2 as a 2 h intravenous (i.v.) infusion on day 1; 
Leucovorin was given at a dose of 400 mg/m2 as a 2-h i.v. infu-
sion, followed by 5-FU 400 mg/m2 as an i.v. bolus, and then, 
2,400 mg/m2 as a 22-h continuous i.v. infusion, on days 1 and 2, 
repeated every 2 weeks (18). A further 4 patients received the 
IRIS regimen; Irinotecan at a dose of 150 mg/m2 as a 1.5-h 
i.v. infusion on day 1, followed by S-1 100 mg/day for 14 days 
perorally, repeated every 3 weeks. The Bevacizumab dose was 
7.5 mg/kg and was administered i.v. every 2 weeks, initially 
over 90 min. The best responses across all time points, which 
were evaluated 2 months following the initial administration 
of the irinotecan-based regimen, were used for classification 
according to the Response Evaluation Criteria In Solid Tumors 
guideline, version 1.1 (19), and assigned complete response 
(CR), partial response (PR), stable disease (SD) or progressive 
disease (PD).
CD‑DST. CD-DST was used to evaluate the sensitivity of 
cancer tissue to SN-38. Briefly, 5 mm cube of colorectal cancer 
specimens obtained by surgery were minced by surgical knife, 
and digested with collagenase, and the dispersed cancer cells 
were incubated in a collagen gel coated flask. Only the viable 
cells adhering to the collagen gel layer were collected and 
added to the reconstructed type I collagen solution (Cellma-
trix Type CD; Kurabo Industries, Ltd., Osaka, Japan). SN-38 
(0.03 µg/ml; LKT Laboratories, Inc., St Paul, MN, USA) and 
5-FU (1 µg/ml; Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan) 
were added to each well. The plate was then incubated for 
24 h at 37˚C. Subsequent to the removal of the medium 
containing the anticancer drug, each well was incubated with 
PCM-2 medium (Kurabo Industries, Ltd.) for 7 days. Neutral 
red was then added to stain the colonies in the collagen gel 
droplets, which were next fixed with formalin. The in vitro 
chemosensitivity effect was expressed as a ratio of the total 
colony volume of the treated group (T) to that of the control 
group (C) (T/C ratio) (20). A T/C ratio of ≤60% was regarded 
as sensitive.
Immunohistochemical staining. All specimens were archived 
as formalin-fixed and paraffin-embedded tissues. Sections 
(3-µm thick) were cut and immunostained using the Ventana 
Discovery XT staining system (Ventana Medical Systems, 
Inc., Tucson, AZ, USA). Normal and cancerous tissues from 
the same patient were mounted onto the same slide to ensure 
identical conditions. Slides were then incubated with a primary 
anti-ABCG2 antibody (clone BXP-21 mouse anti-human mono-
clonal antibody; dilution, 1:500; catalog no. MAB4146; Merck 
Millipore, Darmstadt, Germany) at 37˚C for 32 min, followed 
by incubation with Discovery™ Universal Secondary Antibody, 
a biotinylated immunoglobulin (lg) cocktail of goat anti-mouse 
lgG, goat anti-mouse lgM, goat anti-rabbit lgG and protein 
block (ready for use; catalog no. 760-4205; Ventana Medical 
Systems, Inc.). The immunological reaction was visualized with 
3,3'-diaminobenzidine chromogen (DAB Map Kit; Ventana 
Medical Systems, Inc.), followed by counterstaining with hema-
toxylin. Sections were dehydrated and cover slips were mounted.
Stained slides were examined independently by 
two researchers from the Departments of Surgery and 
Pathology of Shiga University of Medical Science (Otsu, 
Japan). The staining intensity of positive cell membranes was 
classified as negative (no staining), 0; weak, 1; moderate, 2; or 
intense (as strong as in normal colonocytes), 3. The proportion 
of total positive cancer cells with membranous positivity was 
scored as follows: <5%, 0; 5-25%, 1; 26-50%, 2; 51-75%, 3; or 
>75%, 4.
ABCG2 expression was determined by multiplication of the 
values for intensity and proportion, and was classified as low- 
or high-expression for scores of 0-8 or 9-12, respectively (21). 
For heterogeneous signals, the results were based on the most 
intensely stained group of cells. The negative control was 
processed by replacing the primary antibody against ABCG2 
with phosphate-buffered saline.
Statistical analysis. SPSS software, version 17.0 (SPSS, Inc., 
Chicago, IL, USA) and Stata software version 10.1 (Stata-
Corp LP, College Station, TX, USA) were used for statistical 
analyses. In order to compare the differences across strati-
fied groups, the t-test or Wilcoxon test was performed for 
continuous variables, and the χ2 test or Fisher's exact test 
was performed for categorical variables, as appropriate. The 
univariate and multivariate logistic regression or Pearson's χ2 
statistic were used to analyze the effect of clinicopatholog-
ical factors and ABCG2 expression on SN-38 sensitivity, or 
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the discrepancy between these variables, respectively; vari-
ables with P<0.25 were selected as candidates for inclusion 
in the multivariate model (22). A 95% confidence interval 
(CI) for prevalance ratio (PR) were calculated with standard 
errors estimated by the Wald test. Overall survival (OS) was 
defined as the time between the date of initial administra-
tion of the irinotecan-based regimen and mortality or final 
follow-up. Progression-free survival (PFS) was defined as 
the time between the date of initial administration of the 
irinotecan-based regimen and recurrence or final follow-up. 
The survival curves were calculated according to the 
Kaplan-Meier method, and differences between curves were 
assessed using the generalized Wilcoxon test. P<0.05 was 
considered to indicate a statistically significant difference.
Results
Expression of ABCG2 in colorectal cancer tissues. In the 
normal colon mucosa samples, the expression of ABCG2 
was increased along the brush border membranes of normal 
colonocytes (Fig. 1A and B). High expression in the tumor 
was defined as non-intense expression or low proportion of 
ABCG2 positivity (Fig. 1C and D) and the tumor was defined 
as intense expression in 50% or more of the cancer cells, and 
low expression (Fig. 1E and F) The patients were classified 
into low-expression (76 patients; 40%) or high-expression 
(113 patients; 60%) groups, of which the median immunohisto-
chemistry scores were 4.21±0.25 and 10.55±0.15, respectively. 
A three-dimensional distribution of the proportion of positive 
cancer cells and signal intensities are shown in Fig. 1G.
Association between SN‑38 response, ABCG2 expression 
and clinicopathological factors in patients with colorectal 
cancer. The clinicopathological factors of the 189 patients 
are presented in Table I. Briefly, 119 patients possessed colon 
cancer and 70 possessed rectal cancer. The ages of the patients 
ranged between 33 and 88 years (median, 65 years). Moderate 
differentiation (72%) and stage 3 or 4 (54%) tumors were iden-
tified in the majority of patients. ABCG2 expression in rectal 
cancer was significantly increased, compared with expression 
in colon cancer (P=0.019). The median SN-38 T/C ratio was 
significantly increased in the high-expression group, compared 
with the low-expression group (P<0.001). No significant asso-
ciation between the expression levels of ABCG2 and any other 
clinicopathological factors studied was observed, including 
age, gender, histological type, tumor invasion, lymph node 
metastasis, distant metastasis, lymphatic invasion, venous 
invasion and stage of the tumor.
Associations between sensitivity to SN-38 and clinico-
pathological factors were analyzed as categorical variables 
in a univariate analysis (Table II). Patients with increased 
expression of ABCG2 were significantly more resistant to 
SN-38, compared with patients with low expression of ABCG2 
(P<0.001). The sensitivity of increased expression of ABCG2 
to predict the low response to SN-38 by CD-DST was 82%, 
and the specificity was 73%. Other factors, including age, 
gender, differentiation, stage grouping, tumor depth, lymph 
node metastasis, distant metastasis, lymphatic invasion and 
venous invasion, did not associate with sensitivity to SN-38. 
Two selected variables, namely location of the tumor and 
expression of ABCG2, were analyzed in a multivariate 
  A   B
  C   D
  E   F
  G
Figure 1. ABCG2 expression was evaluated by immunohistochemistry in normal colon and colorectal cancer tissues. (A and B) ABCG2 protein signal (brown) 
was strongest along the brush border membranes of normal colonocytes (patient with colon cancer). (C and D) ABCG2 expression in cancerous gland (left 
side) is weaker than that of normal ground surrounding the tumor (right side). (Low expression group, colon cancer).  (E and F) Intense ABCG2 expression in 
the cancerous glands (right upper side) is similar to normal colonocytes around the tumor (left lower side) (High expression group, rectal cancer). Scale bar, 
200 µm and magnification, x100 in panels A, C and E. Scale bar, 50 µm and magnification, x400 in panels B, D and F. (G) ABCG2 expression was quantified 
by multiplication of the scores for intensity and proportion, and patients were classified into low- or high-expression groups, according to scores of 0-8 or 9-12, 
respectively. ABCG2, adenosine triphosphate-binding cassette sub-family G (WHITE) member 2 (Junior blood group).
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regression model. Patients with increased expression of 
ABCG2 were the strongest indicators of resistance to SN-38 
[prevalence ratio (PR), 11.77; 95% confidence interval (CI), 
5.83-23.76; P<0.001).
ABCG2 expression and clinical response to irino‑
tecan-based chemotherapy. Eligibility criteria for tumor 
response to irinotecan-based regimens were identified in 
17 patients, of which, 5 (29%) were classified as PR and 
12 (71%) as non-responders, including 11 SD and 1 PD. 
The patient and tumor characteristics for responders 
and non-responders are shown in Table III. There were 
no significant differences between the two groups, with 
the exception of the expression levels of ABCG2 and 
Table I. Clinicopathological factors and protein expression levels of adenosine triphosphate-binding cassette sub-family G 
(WHITE) member 2 (Junior blood group) in 189 patients with colorectal cancer.
 All patients, Low-expression High-expression
Characteristics n (%) group, n (%) group, n (%) P-value
Total 189 (100) 76 (40) 113 (60)
Age, years
  Median 65 64 66 0.271a
  Range 33-88 33-88 43-86
Gender
  Female   77 (41) 29 (38) 48 (42) 0.659b
  Male 112 (59) 47 (62) 65 (58)
Tumor location
  Colon 119 (63) 56 (74) 63 (56) 0.019b
  Rectum   70 (37) 20 (26) 50 (44)
Differentiation
  Well   39 (21) 15 (20) 24 (21) 0.733b
  Moderate 136 (72) 54 (71) 82 (73)
  Poor 14 (7) 7 (9) 7 (6)
Stage grouping
  Duke's A   87 (46) 35 (46) 52 (46) 1.000b
  Duke's B, C 102 (54) 41 (54) 61 (54)
Tumor depth
  pT1,2   35 (19)   9 (12) 26 (23) 0.081b
  pT3,4 154 (81) 67 (88) 87 (77)
Lymph node metastasis
  N0   94 (50) 38 (50) 56 (50) 1.000b
  N1,2   95 (50) 38 (50) 57 (50)
Distant metastasis
  M0 156 (83) 60 (79) 96 (85) 0.383b
  M1   33 (17) 16 (21) 17 (15)
Lymphatic invasion
  Ly0,1 133 (70) 50 (66) 83 (73) 0.333b
  Ly2,3   56 (30) 26 (34) 30 (27)
Venous invasion
  V0,1 126 (67) 49 (64) 77 (68) 0.714b
  V2,3   63 (33) 27 (36) 36 (32)
SN-38 effect, T/C
  Median 66 55 73 <0.001a 
Range 21-100 21-100 32-100
  Sensitive, T/C <60   77 (41) 56 (74) 21 (19) <0.001b
  Resistant, T/C ≥60 112 (59) 20 (26) 92 (81)
aP-values were obtained from Student's t-tests. bP-values were obtained from χ2 tests. TNM, tumor-node-metastasis; T/C, ratio of the total 
colony volume of the treated group (T) to that of the control group (C).
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the effect of SN-38 by CD-DST. Increased expression of 
ABCG2 was observed in 11 of 12 non-responders, whereas 
4 of 5 responders exhibited decreased expression of ABCG2. 
The sensitivity of increased ABCG2 expression to predict the 
resistance to irinotecan-based chemotherapy was 92%, and 
the specificity was 80%. The results of CD-DST indicated 
sensitivity to SN-38 in 4 of 5 responders (80%), compared 
with 2 of 12 non-responders (17%); the difference between 
which was significant (P=0.028).
The association between treatment characteristics and PFS 
is shown in Table IV. The median PFS of the responder group 
was significantly longer, compared with the non-responder 
group (372 vs. 104 days; P=0.013). The median PFS was 
significantly longer in the patients with low-expression of 
ABCG2 than those with high-expression of ABCG2 (242 vs. 
104 days; P=0.047, Fig. 2). The median PFS of the 17 patients 
sensitive to SN-38 tended to be longer than the median PFS 
of resistant patients; however, this result was not statistically 
Table II. Multivariate analysis of clinicopathological factors and SN-38 sensitivity in 189 patients with colorectal cancer.
   Univariate Multivariate analysis
 Sensitive, Resistant, analysis ----------------------------------------------------------------------------
Factors n (%) n (%) P-valuea Adjusted PR (95% CI) P-valueb
Total 77 (41) 112 (59)
Age, years
  <65 40 (52) 59 (53) 1.000  
  ≥65 37 (48) 53 (47)   
Gender
  Female 35 (45) 42 (38) 0.346  
  Male 42 (55) 70 (63)   
Tumor location
  Colon 55 (71) 64 (57) 0.065 Ref 0.446
  Rectum 22 (29) 48 (43)  1.33 (0.63-2.77)
Differentiation
  Well 16 (21) 23 (21) 0.756  
  Moderate 54 (70) 82 (73)  
  Poor 7 (9) 7 (6)
Stage grouping
  Duke's A 36 (47) 51 (46) 0.987  
  Duke's B,C 41 (53) 61 (54)   
Tumor depth
  pT1,2 11 (14) 24 (21) 0.093  
  pT3,4 66 (86) 88 (79)  
Lymph node metastasis
  N0 40 (52) 54 (48) 0.722
  N1,2 37 (48) 58 (52)
Distant metastasis
  M0 64 (83) 92 (82) 1.000  
  M1 13 (17) 20 (18)
Lymphatic invasion
  Ly0,1 53 (69) 80 (71) 0.824
  Ly2,3 24 (31) 32 (29)
Venous invasion
  V0,1 53 (69) 73 (65) 0.714
  V2,3 24 (31) 39 (35)
ABCG2 expression
  Low 56 (73) 20 (18) <0.001 Ref <0.001
  High 21 (27) 92 (82)  11.77 (5.83-23.76)
aP-values were obtained from χ2 tests. bP-values were obtained from Wald tests. TNM, tumor-node-metastasis; PR, prevalence ratio; CI, 
confidence interval; ABCG2, adenosine triphosphate‑binding cassette sub‑family G (WHITE) member 2 (Junior blood group); Ref, reference.
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Table III. Clinicopathological characteristics and response to irinotecan-based chemotherapy of 17 patients with colorectal cancer.
 All patients, Responders (n=5), Non-responders (n=12),
Characteristics n (%) n (%) n (%) P-value
Age, years
  Median 60 67 58 0.246a
  Range 33-77 56-76 33-77 
Gender
  Female   6 (35)   1 (20)   5 (42) 0.600b
  Male 11 (65)   4 (80)   7 (58)
Tumor location
  Colon   8 (47)   3 (60)   5 (42) 0.620b
  Rectum   9 (53)   2 (40)   7 (58)
Differentiation
  Well   0 (0) 0 (0) 0 (0) 0.515b
  Moderate 15 (88)   4 (80) 11 (92)
  Poor   2 (12)   1 (20) 1 (8)
Stage grouping
  Duke's A   1 (6) 0 (0) 1 (8) 1.000b
  Duke's B   4 (24) 1 (20) 3 (25)
  Duke's C   12 (70) 4 (80) 8 (57)
No. of metastatic sites
  1   7 (41)   2 (40)   5 (42) 1.000b
  2   8 (47)   3 (60)   5 (42)
  3   2 (12) 0 (0)   2 (17)
Line of chemotherapy
  1st   4 (23)   1 (20)   3 (25) 0.744b
  2nd   6 (35)   2 (40)   4 (33)
  3rd   4 (23)   2 (40)   2 (17)
  Other   3 (18) 0 (0)   3 (25)
Chemotherapy regimen
  FOLFIRI 13 (76)   4 (80)   9 (75) 1.000b
  IRIS   4 (23)   1 (20)   3 (25)
Bevacizumab
  Without   8 (47)   3 (60)   5 (42) 0.620b
  With   9 (53)   2 (40)   7 (58)
ABCG2 expression
  Low   5 (29)   4 (80) 1 (8) 0.010b
  High 12 (71)   1 (20) 11 (92)
SN-38 effect, T/C
  Median 69 59 73 0.113a
  Range 31-100 31-87 32-100
  Sensitive, T/C <60   6 (35)   4 (80)   2 (17) 0.028b
  Resistant, T/C ≥60 11 (65)   1 (20) 10 (83)
5-FU effect, T/C
  Median 71 64 74 0.342a
  Range 32-100 32-81 42-100
  Sensitive, T/C <60   3 (18)   1 (20)   2 (17) 1.000b
  Resistant, T/C ≥60 14 (82)   4 (80) 10 (83)
aP-values were obtained from Wilcoxon rank-sum tests. bP-values were obtained from Fisher's exact tests. Stage grouping: Dukes A, pT1 or 
pT2, and N0; Dukes B, pT3 or pT4, and N0; Dukes C, any pT, and N1 or N2; FOLFIRI, leucovorin, fluorouracil and irinotecan; IRIS, oral 
fluorouracil and irinotecan; ABCG2, adenosine triphosphate‑binding cassette sub‑family G (WHITE) member 2 (Junior blood group); T/C, 
ratio of the total colony volume of the treated group (T) to that of the control group (C); FU, fluorouracil.
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significant (242 vs. 110 days; P=0.061). Other factors, including 
the line or content of the chemotherapy and sensitivity to 
5-FU, did not affect the median PFS. The median OS of the 
17 patients was 554 days. The median OS of the patients with 
increased and decreased ABCG2 expression were 449 days 
and 554 days, respectively, which showed no significant differ-
ence (P=0.505).
Discussion
The resistance of cancer cells with ABCG2 overexpression to 
SN-38 is most likely due to the efflux transportation of SN-38 
and SN-38 glucuronide out of the cells (23). ABCG2 has been 
the subject of numerous studies on leukemia and several 
solid tumors; however, there are numerous conflicting reports 
regarding the association between ABCG2 expression and the 
outcome of chemotherapy or survival (24,25). The present 
study investigated whether ABCG2 expression is associated 
with SN-38 resistance in human colorectal cancer, and demon-
strated that the increased expression of ABCG2 may predict 
resistance to SN-38 treatment, with a sensitivity of 82%, and 
Table IV. Treatment characteristics and association with PFS following irinotecan-based chemotherapy in 17 patients with 
colorectal cancer.
 PFS following irinotecan-based chemotherapy
 -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
Characteristics Patients, n (%) Median PFS, days Generalized Wilcoxon
Line of chemotherapy
  1st   4 (23) 176 0.267
  2nd   6 (35) 104 
  3rd   4 (23) 242
  Other   3 (18) 104
Chemotherapy regimen
  FOLFIRI 13 (76) 167 0.773
  IRIS  4 (23) 104 
Bevacizumab
  Without   8 (47) 104 0.631
  With   9 (53) 176 
ABCG2 expression
  Low   5 (29) 242 0.047
  High 12 (71) 104 
SN-38 effect, T/C
  Sensitive, T/C <60   6 (35) 242 0.061
  Resistant, T/C ≥60 11 (65) 110
5-FU effect, T/C
  Sensitive, T/C <60   3 (18) 200 0.381
  Resistant, T/C ≥60 14 (82) 116
Response
  Responder   5 (29) 372 0.013
  Non-responder 12 (71) 104 
PFS, progression-free survival; FOLFIRI, leucovorin, fluorouracil and irinotecan; IRIS, oral fluorouracil and irinotecan; ABCG2, adenosine 
triphosphate-binding cassette sub-family G (WHITE) member 2 (Junior blood group); T/C, ratio of the total colony volume of the treated group 
(T) to that of the control group (C); FU, fluorouracil.
  
Figure 2. Kaplan-Meier curves for PFS of patients with colorectal cancer, 
according to their expression levels of adenosine triphosphate-binding cas-
sette sub-family G (WHITE) member 2 (Junior blood group). The median 
PFS of the low‑expression group was significantly longer than that of the 
high-expression group (242 vs. 104 days, P=0.047). PFS, progression-free 
survival; ABCG2, adenosine triphosphate‑binding cassette sub‑family G 
(WHITE) member 2 (Junior blood group).
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the lack of response to irinotecan-based chemotherapy, with a 
sensitivity of 92%. Patients with primary tumors that demon-
strated increased ABCG2 expression were at an increased 
(11.77-fold) risk of a negative response to irinotecan-based 
chemotherapy (P<0.001).
Deitrich et al (26) showed that the downregulation of 
ABCG2 led to the accumulation of carcinogens, including 
2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine, in the 
colorectal adenomas of mice and humans, and suggested 
that this may promote the adenoma-carcinoma sequence. 
Gupta et al (16) reported that the expression of ABCG2 mRNA 
and protein was abundant in the normal colon and decreased 
in colon cancer tissue. However, the possibility of alterations 
in ABCG2 expression during the progression of a carcinoma 
remained to be clarified. The present study demonstrated 
that ~60% of patients that possessed tumors belonged to the 
high-ABCG2-expression group.
A few studies have investigated the expression of ABCG2 
mRNA in human colorectal cancer, but to the best of our 
knowledge, none have reported associations with the effects 
of chemotherapy, including irinotecan (17,27). Associations 
between the increased expression of ABCG2 with lymph 
node metastasis and the clinical stage of breast cancer (28), 
and with poor differentiation in glioma cells (29), have been 
reported. However, the present study did not indicate any 
significant associations with clinicopathological factors, with 
the exception of the precise location of the primary tumor. The 
expression level of ABCG2 in rectal cancer was significantly 
increased compared with in colon cancer (P=0.019). In addi-
tion, the number of patients whose tumors were resistant to 
SN-38 was increased for rectal cancer compared with colon 
cancer, although this was not statistically significant (P=0.065). 
No evidence was identified that explained this result; therefore, 
future investigation is required in order to understand this 
phenomenon.
Topoisomerase I mutations (30), ABCG2 overexpres-
sion (17) in cancer cell lines and gene expression profiles (31) 
in human colorectal cancer tissue have been suggested to be 
involved in the development of resistance to irinotecan. The 
expression of topoisomerase I has been investigated as a predic-
tive factor for patient response to irinotecan in vitro (32), but no 
effects on response, time to progression or OS have been identi-
fied in clinical studies (33). In the present study, despite having 
only 17 eligible patients, the increased expression of ABCG2 
was significantly associated with resistance to irinotecan-based 
chemotherapy (P=0.01) and a shorter PFS (P=0.047). These 
data suggest that ABCG2 may be useful as a biomarker to 
predict chemoresistance to SN-38 of primary colorectal cancer 
tissues. Patients with recurrent or metastatic colorectal cancer 
that possess primary tumors with increased ABCG2 expression 
may, therefore, avoid irinotecan-based chemotherapy, enabling 
treatment with other regimens instead. Similarly, patients with 
decreased ABCG2 expression may possibly receive more 
benefits from irinotecan-based regimens compared patients 
with increased expression. The median OS of the patients with 
low-ABCG2-expression (n=5) was not significantly different 
compared with those with high-expression (n=12) (P=0.505). 
This may be due to the majority of patients that were judged as 
PD receiving additional lines of chemotherapy, following the 
irinotecan-based chemotherapy.
ABCG2 immunohistochemical staining of primary 
colorectal cancer tissues is easy to perform, and may provide 
information regarding the chemosensitivity of patients to 
irinotecan. Prospective studies with increased numbers 
of patients are required to confirm this hypothesis. An 
inhibitor of ABCG2 may possibly be used as an additional 
agent with irinotecan-based regimens in patients defined 
as irinotecan-resistant due to the increased expression of 
ABCG2. In conclusion, the increased expression of ABCG2 
may be involved in SN-38 resistance in colorectal cancer and 
may be a useful predictive biomarker for use in patients that 
are under consideration for treatment with irinotecan-based 
chemotherapy.
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